|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines显示文摘 | Mora S Musunuru K Blumenthal RS | 2009 | Clin Chem2009，55，2： | 1 |
| 2 | Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neuronal degeneration 显示文摘 | Musunuru K Darnell RB | 2001 | Annu Rev Neurosci2001，24，3： | 1 |
| 3 | Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia 显示文摘 | Musunuru K Pirruccello JP Do R | 2010 | N Engl J Med2010，363，23： | 1 |
| 4 | Regulatory elements in noncoding DNA in the chro-mosome 9p21 locus显示文摘 | Musunuru K | 2011 | Circ Cardiovasc Genet2011，4，3： | 1 |
| 5 | Ionmobility analysis of lipoprotein subfractions identifies threeindependent axes of cardiovascular risk显示文摘 | Musunuru K Orho-Melander M Caulfield MP | 2009 | ArteriosclerThromb Vasc Biol2009，29，11： | 1 |
| 6 | The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines显示文摘 | Mora S Musunuru K Blumenthal RS | 2009 | Clin Chem2009，55，2： | 1 |
| 7 | The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis re- gression trial:a return to first principles显示文摘 | Musunuru K Blumenthal SR | 2008 | Clin CardioI2008，31，6： | 1 |
| 8 | Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia显示文摘 | Musunuru K Pirruccello JP Do R | 2010 | N Engl J Med2010，363，23： | 1 |
| 9 | Atherogenic dyslipidemia: cardiovascular risk and dietary intervention显示文摘 | Musunuru K | 2010 | Lipids2010，45，10： | 1 |
| 10 | Exome sequencing,ANGPTL3 mutations,and familial combined hypolipidemia显示文摘 | Musunuru K Pirruccello JP Do R | 2010 | N Engl J Med2010，363，： | 1 |
| 11 | From noncoding variant to phenotype via SORT1 at the lp13 cholesterol locus 显示文摘 | Musunuru K Strong A Frank-Kamenetsky M | 2010 | Nature2010，466，7307： | 1 |
| 12 | Clinical efficacy and safety of statins in managing cardiovascular risk显示文摘 | Kapur NK Musunuru K | | 0，，02： | 1 |
| 13 | Biological,clinical and population relevance of 95 loci for blood lipids显示文摘 | Teslovich TM Musunuru K Smith AV | 2010 | Nature2010，466，7307： | 1 |
| 14 | Clinical efficiency and safety of statins in managing cardiovascular risk 显示文摘 | KAPUR N K MUSUNURU K | 2008 | Vase Health Risk Manag2008，4，2： | 1 |
| 15 | Biological, clinical and population relevance of 95 loci for blood lipids 显示文摘 | Teslovich TM Musunuru K Smith AV | 2010 | Nature2010，466，： | 1 |
| 16 | Biological, clinic'A and population relevance of 95 lcci for blood lipids 显示文摘 | Slovich TM Musunuru K Smith AV | 2010 | Nature2010，466，7307： | 1 |
| 17 | Bio- logical,clinical and population relevance of 95 loci for blood lipids显示文摘 | Teslovich T M Musunuru K Smith A V | 2010 | Nature2010，466，7307： | 1 |
| 18 | Genetics of coronary heart dis- ease 显示文摘 | Musunuru K Kathiresan S | 2010 | Annu Rev Genomics Hum Genet2010，11，： | 1 |
| 19 | Biological, clinical and population relevance of 95 loci for blood lipids 显示文摘 | Teslovich TM Musunuru K Smith AV | 2010 | Nature2010，466，7307： | 1 |
| 20 | Clinical efficacy and safety of statins in managing cardiovascular risk显示文摘 | Kapur NK Musunuru K | 2008 | Vasc Health Risk Manag2008，4，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员